Menopausal VMS Education in Primary Care: Build Trust First, Says One Clinician
Building trust with patients early on will help them feel comfortable discussing their symptoms and treatment preferences, says JoAnn Pinkerton, MD.
Menopause is often under-recognized and undertreated, JoAnn Pinkerton, MD, told Patient Care Online in a recent interview. Educating women on menopause and available treatment options is important to help increase awareness. "If physicians ask women about symptoms and listen to what they are experiencing, what they've tried that hasn't worked, and what they've heard or read, and then build a relationship built on trust, that will open the door so you can start to address whether or not they have significant symptoms and what types of therapy they might be a candidate for," Dr Pinkerton, a professor of obstetrics and gynecology and division director of Midlife Health at the University of Virginia Health System in Charlottesville, Virginia, said. She explains more in the video below.
Dr Pinkerton is also the national lead for the OASIS clinical trial program examining the efficacy and safety of elinzanetant for moderate-to-severe VMS. For details on the OASIS studies, check out part 1 of our interview series: Elinzanetant for Menopausal VMS: OASIS Lead Investigator Discusses Results, Side Effects, Next Steps
